Clinical Trials · NCT03562091

Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel

Name: Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/ALanreotide

Phase: N/A
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 115
Start date: Jul 2018
Locations: 1 site, France
Primary endpoint: Absolute variation on the score (standardized on a scale from 0 to 100) of the 3 targeted dimensions (disease, treatments and supportive care) of the self-administered Quality of Life Questionnaire (QLQ) QLQINFO25

View Lanreotide compound reference